Welcome to Quorum Innovations
Harnessing the Power of the Human Microbiome for Barrier Defense and Health Innovation
At Quorum Innovations, we believe the future of medicine begins within. The human body is host to a vast, dynamic ecosystem—the human microbiome—that outnumbers human cells ten to one. While the human genome contains about 23,000 genes, the microbiome brings over 3.5 million genes to the table. This immense genetic reservoir supports not only core physiological functions but also critical biological defenses—including protection against environmental toxins, chemical threats, and microbial invaders. It represents a transformative frontier for advancing human health, resilience, and disease prevention.
The BioEsse Skin Care System is a breakthrough from Quorum Innovations and contains Qi Probiomics, our patented extract derived from the most natural of all probiotic sources, the human microbiome itself. www.bioesseprobiotics.com
Qi601™ Biofilm Shield™ with Probiomic® technology protects you from microplastics in food and water you unknowingly ingest each day. It is the supplement that empowers health-conscious individuals to take control of their health by naturally binding up microplastics, using advanced Probiomic® technology with a patented heat-inactivated biofilm matrix derived from probiotic Lactobacillus fermentum. Only Qi601 has this.
https://qi601.com
Our Mission
Quorum Innovations is committed to developing rational, safe interventions derived from the human microbiome. Our focus is on barrier defense technologies that work with the body’s native microbial ecosystem to enhance protection at critical interfaces—gut, skin, airway, and intimate mucosa.
Physician-Scientist Founded
Quorum Innovations was founded by Dr. Eva Berkes and Dr. Nicholas Monsul, both physician-scientists with extensive academic and clinical training.
Dr. Berkes completed her medical education at the University of Florida and then pursued advanced fellowship training at the Scripps Research Institute in La Jolla, California, where her work focused on integrating clinical care and molecular research in immunology and microbiome science.
Dr. Monsul completed his surgical training at the Yale University School of Medicine, followed by fellowship training at The Johns Hopkins Hospital in Baltimore, where he joined the academic faculty. While at Hopkins, he was actively involved in basic science research and trained both residents and fellows, cultivating a translational approach to medical innovation rooted in frontline experience.
Together, their combined expertise drives Quorum’s mission to develop clinically meaningful, microbiome-based technologies that support human health through natural, science-based solutions.
Quorum has been awarded over 40 patents across major global jurisdictions—including the United States, European Union, China, Japan, Korea, and other regions in South America and Southeast Asia. These patents reflect the scientific originality and broad international relevance of Quorum’s barrier defense technologies.
Recognized by DARPA and Bayer Pharmaceuticals
Quorum was selected by the Defense Advanced Research Projects Agency (DARPA) to develop microbiome-based therapeutics for defense against chemical and biological weapons—critical tools for protecting warfighters and first responders. Our company was awarded two DARPA grants in recognition of this work.
This technology for barrier defense has applicability to many common issues in today’s modern society, including environmental toxin exposure, compromised epithelial integrity, inflammatory skin and gut conditions, and immune imbalances associated with urban living, chronic stress, and dietary disruption.
In parallel, Bayer Pharmaceuticals identified Quorum’s technology for a women’s health initiative, supporting the development of barrier defense products for women’s intimate care, based on microbiome-derived formulations.
The Quorum Vision
At the intersection of medicine, microbiology, and biotechnology, Quorum Innovations is pioneering a new class of interventions—from national defense to personal health. We are unlocking the therapeutic power of nature’s original allies: the beneficial microbes that live within and protect us every day.
Our work is grounded in the understanding that the human microbiome thrives on the very surfaces that define and defend us—the skin, the intestinal lining, the vaginal epithelium, and other mucosal barriers. These surfaces are not passive boundaries; they are living, dynamic interfaces that rely on the microbiome to maintain integrity, defend against pathogens, neutralize toxins, and modulate immune responses.
By preserving and enhancing these microbiome-supported surfaces, we aim to fortify the body’s first line of defense, naturally and sustainably.